Summer 2026
Software Engineer in Test Intern
Posted on 4/20/2026
Veeva Systems
10,001+ employees
Cloud-based quality, regulatory, and claims management
Compensation Overview
CA$25 - CA$30/hr
Toronto, ON, Canada
In Person
 QA & Testing |
|---|
 Software Engineering |
|---|
Get referred to Veeva Systems
See people who can refer or advise you
- Usage of Java, JUnit, Unix, and MySQL (or equivalent Database experience)
- Computer science fundamentals (data structures, algorithms, OO design, and software design)
- Capable of conducting root cause analysis of any defects found
- Experience with testing web-based applications
- An ideal candidate for this role is a self-starter with a keen eye for detail who loves technical challenges and who wants to learn. You will take pride and ownership of key parts of the software and certify its quality and correctness before delivery to the customer
- You will be developing automated test cases using our testing framework for API and/or UI
- Participate in functional, system, integration, and regression testing activities
- Work with Software Engineers and Product Managers to deliver a user experience that solves the business needs
- Create and improve documentation for test cases and automation test scripts
- Become a Subject Matter Expert in your test areas
- Relevant internship/co-op experience is a plus
- Basic knowledge of common automation tools and BDD testing framework is highly desirable
- Basic knowledge of Microservice architecture
Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2007
Get referred to Veeva Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 fiscal 2027 revenue hit $928 million, up 18%; guidance rose August 26, 2026.
- Biogen and Lilly validated Vault CRM globally, accelerating top-20 biopharma migrations.
- Veeva opened Penn District offices September 1, 2026, signaling hiring and customer-facing expansion.
What critics are saying
- Thomas Schwenger exits October 2, 2026, removing a long-tenured customer chief during CRM migrations.
- Salesforce still battles Veeva with horizontal CRM, pressuring pricing if top pharma delays conversion.
- A failed Falcon or CRM rollout would expose Veeva’s platform credibility and stall expansion.
What makes Veeva Systems unique
- Veeva dominates life-sciences CRM: Eli Lilly, Biogen, and Regeneron committed in August 2026.
- Falcon Safety integrates with Oracle Argus and ArisGlobal, widening adoption beyond Veeva stacks.
- Vault CRM’s regulated-workflow moat spans commercial, safety, and clinical operations for biopharma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Parental leave
PTO
Free food
Health, dental, & vision insurance
Gym membership reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -1%Veeva Systems is well-positioned for growth due to its strong product portfolio and solid second-quarter fiscal 2027 performance, though market saturation remains a concern. The cloud-based software provider for life sciences has gained 25.7% year-to-date, outpacing the industry's 11.3% and the S&P 500's 10.8% growth. The company's Development Cloud portfolio is driving expansion across clinical development, quality management, and regulatory operations. Vault CRM adoption advanced significantly in Q2, with Veeva securing 12 of the top 20 biopharma CRM commitments. Commercial subscription revenues rose 13% year-over-year to $347.4 million. The company projects 35% growth over the next five years and maintains a market capitalisation of $45.6 billion.
Michael Burry trimmed his position in Veeva Systems after the stock nearly doubled in roughly 10 weeks. The investor reduced his holding to around 3% of his portfolio whilst maintaining exposure to potential upside. Veeva surged 89% from a June low of $150.39 to $285 by late August. The catalyst was the company's Q2 fiscal 2027 earnings, which beat expectations across all metrics. Revenue grew 18% year-over-year to $928 million, exceeding the $905 million consensus. Adjusted earnings per share came in at $2.35 versus $2.22 expected. Burry described the move as "playing with the house's money" on a position he continues to favour. The trim represents disciplined position management rather than a bearish call on Veeva's prospects.
Veeva signs 62,223 SF office lease at The PENN District in Midtown Manhattan. September 1, 2026 NEW YORK CITY - Veeva has signed a 62,223-square-foot office lease at The PENN District, a two-building, 4.4 million-square-foot development in Midtown Manhattan. The provider of cloud software, AI, data and consulting services for the life sciences industry will occupy the entire 11th floor of PENN 2 on a 12-year lease. Jim Wenk and Kirill Azovtsev of Savills represented Veeva in the lease negotiations. The landlord, Vornado Realty Trust, was self-represented.
Veeva Systems announced Veeva Falcon Safety, an agentic safety operations product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies. The solution will work with Veeva Safety and integrate with any E2B-compliant safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance. Falcon Safety aims to reduce costs, increase speed, and maintain compliance across safety operations. The product was developed through collaboration with case processors, pharmacovigilance experts, and safety specialists globally. The solution is planned for early adopter availability in November 2026. It forms part of Veeva AI, the company's industry-specific artificial intelligence solutions for life sciences. Veeva Systems currently serves more than 1,500 customers, ranging from major pharmaceutical companies to emerging biotechs.
Veeva Systems reported fiscal Q2 revenue of $928 million, up 18% year-over-year, with subscription revenue rising 16% to $766.8 million. GAAP operating income increased 40% to $275 million, pushing the operating margin to 29.6% from 24.8%. However, the prior-year quarter included a $30.6 million litigation charge. Adjusting for this makes the underlying margin expansion closer to one percentage point. The company now has over 180 customers live on Vault CRM, including five of the top 20 biopharma companies, with 12 top-20 firms committed globally. Veeva added more than 30 clinical customers and surpassed 100 Safety customers. Non-GAAP operating income rose 18% to $415.9 million, with margins edging up to 44.8% from 44.7%. GAAP operating cash flow remained flat at $238.7 million year-over-year.